Alkermes plc (ALKS) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase 2 study “A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2” tests Alkermes’ ALKS 2680 in adults with narcolepsy type 2. It aims to see if the drug safely reduces daytime sleepiness versus placebo, a key factor for future late-stage trials and market potential.
The treatment is an oral tablet called ALKS 2680, given once daily at different doses. It is designed to help patients stay more awake during the day and improve function, compared with a look‑alike placebo pill.
The trial is an interventional Phase 2 study with patients randomly assigned to different ALKS 2680 doses or placebo. It uses a double-blind design where patients, doctors, and assessors do not know who receives the active drug, and the main goal is to test treatment benefits and safety.
The study was first submitted on 2024-08-13, marking the formal start of the clinical record. The most recent update was posted on 2026-02-25, signaling that the information is current and that the sponsor has refreshed the status and details.
With the trial now listed as completed, investors will watch closely for top-line data and any move toward Phase 3. Positive safety and efficacy signals could lift Alkermes plc (ALKS) sentiment, though the company will face competition from existing narcolepsy players like Jazz Pharmaceuticals and others in the sleep-disorder space.
The study has been recently updated on the ClinicalTrials portal, and further details and future milestones will be available there as the ALKS 2680 program advances.
To learn more about ALKS’s potential, visit the Alkermes plc drug pipeline page.